Galera Therapeutics completes acquisition of Nova Pharmaceuticals

Galera’s development strategy shifts from toxicity reduction to anti-cancer therapeutics, with three trials in patients with highly resistant subsets of advanced breast cancer.

Read more at globenewswire.com